Skip to main content

Table 3 Clinical efficacy of NGX-4010 in patients with PHN duration ≥ 6 months (180 days)

From: Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia

NPRS Scores NGX-4010
(n = 86)
Control
(n = 43)
P-value
Baseline, LS mean (SE) 5.4 (0.17) 5.2 (0.24)  
   95% CI 5.05, 5.72 4.77, 5.72  
Change, mean (SE)    
   Baseline to weeks 2 to 8 -1.8 (0.20) -1.4 (0.29) 0.072
   95% CI -2.18, -1.38 -1.92, -0.79  
   Baseline to weeks 2 to 12 -1.8 (0.20) -1.3 (0.28) 0.160
   95% CI -2.23, -1.44 -1.90, -0.78  
Percent Change, mean (SE)    
   Baseline to weeks 2 to 8 -37.6 (3.66) -23.4 (5.21) 0.0291
   95% CI -44.85, -30.35 -33.74, -13.10  
   Baseline to weeks 2 to 12 -37.5 (3.76) -25.5 (5.35) 0.069
   95% CI -44.98, -30.10 -36.06, -14.88  
Patients with ≥ 30% reduction, %    
   Baseline to weeks 2 to 8 49 40 0.090
   Baseline to weeks 2 to 12 50 44 0.277
Patients with ≥ 50% reduction, %    
   Baseline to weeks 2 to 8 35 30 0.270
   Baseline to weeks 2 to 12 40 28 0.065
PGIC    
   Improved (very much, much)    
   Week 4, n 84 40  
N (%) 31 (37) 14 (35) 1.0000
   Week 8, n 78 35  
N (%) 34 (44) 10 (29) 0.1487
   Week 12, n 81 41  
N (%) 32 (40) 8 (20) 0.0403